BlossomHill doses first patient in SOLARA study’s expansion cohorts
BlossomHill Therapeutics has dosed the first subject in the expansion cohorts of the SOLARA Phase I/II trial to evaluate BH-30643 …
BlossomHill Therapeutics has dosed the first subject in the expansion cohorts of the SOLARA Phase I/II trial to evaluate BH-30643 …
Lighthouse Pharmaceuticals has secured a grant of $49.2m from the National Institute on Aging (NIA), a division of the National …
In a bid to prioritise more human-relevant models, the US Food and Drug Administration (FDA) has enforced a plan to …
AbbVie’s star Janus kinase (JAK) inhibitor, Rinvoq (upadacitinib), has met its primary endpoints in a second Phase III study in …
The regulatory landscape across the Asia-Pacific (APAC) region is evolving rapidly, and pharmaceutical companies must adapt to maintain compliance, mitigate …
In a bid to prioritise more human-relevant models, the US Food and Drug Administration (FDA) has enforced a plan to …
AbbVie’s star Janus kinase (JAK) inhibitor, Rinvoq (upadacitinib), has met its primary endpoints in a second Phase III study in …
The regulatory landscape across the Asia-Pacific (APAC) region is evolving rapidly, and pharmaceutical companies must adapt to maintain compliance, mitigate …
Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, comparing its shingles …
US-based Tyra Biosciences has dosed the first paediatric participant in the dose-escalation/dose-expansion Phase II BEACH301 trial designed to assess the …
The UK’s National Institute for Health and Care Excellence (NICE) has recommended a new combination regimen in metastatic urothelial carcinoma …
In September 2025, clinical development and clinical operations professionals will gather and discuss the current challenges in running clinical trials …
Precision immunology company Scipher Medicine has introduced the ClinicalTrialRank.com AI platform to the public, designed to forecast the likelihood of …
The US Food and Drug Administration (FDA) has given Rocket Pharmaceuticals approval to continue its pivotal Phase II trial of …
Neurizon Therapeutics’ disease-modifying drug NUZ-001 has been shown to be safe and effective over 2.5 years of dosing in patients …